Answers are grounded in this paper and cite their sources.
Review explores microbial metabolites' impact on drug effects in hematologic malignancies, suggesting new therapeutic directions.
The gut microbiome’s metabolome critically shapes drug efficacy and toxicity in hematologic malignancies. This review explores how microbial metabolites influence chemotherapy, immunotherapy, and transplant outcomes, and how they can be harnessed as biomarkers and therapeutic targets. Moving from association to intervention, we outline a pathway toward metabolome-informed precision oncology, transforming the “second genome” into a actionable ally for improved cancer therapy.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: